LYEL
NASDAQ · Biotechnology
Lyell Immunopharma Inc
$20.89
+1.19 (+6.04%)
Open$20.04
Previous Close$19.70
Day High$21.20
Day Low$19.55
52W High$45.00
52W Low$7.65
Volume—
Avg Volume121.9K
Market Cap458.87M
P/E Ratio—
EPS$-22.26
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+33.8% upside
Current
$20.89
$20.89
Target
$27.95
$27.95
$18.45
$27.95 avg
$35.39
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 98.3K | 549.2K | 107.82M |
| Net Income | -548,444,051 | -2,759,081,307 | -16,079,673 |
| Profit Margin | -562,285.3% | -534,171.0% | -14.9% |
| EBITDA | -555,539,280 | -2,950,040,894 | -19,078,562 |
| Free Cash Flow | — | — | -8,704,547 |
| Rev Growth | -82.1% | -82.1% | +2.1% |
| Debt/Equity | — | — | 0.51 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |